{
  "nctId": "NCT07183462",
  "briefTitle": "Azithromycin and Ampicillin for Late PPROM",
  "officialTitle": "Azithromycin and Ampicillin for Late PPROM",
  "protocolDocument": {
    "nctId": "NCT07183462",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2025-06-01",
    "uploadDate": "2025-07-07T16:41",
    "size": 186123,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT07183462/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 311,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2025-09-10",
    "completionDate": "2029-07-31",
    "primaryCompletionDate": "2029-06-30",
    "firstSubmitDate": "2025-06-04",
    "firstPostDate": "2025-09-19"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Maternal age 18-50\n* Premature rupture of membranes\n* Gestational age 34.0 and 36.4 weeks\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Multiple gestations\n* Individuals in active labor (defined as 3 cm dilatation and 80% effacement or more. or regular uterine construction of more than 4 in 10 minutes)\n* Meconium stain amniotic fluid\n* Non-reassuring fetal heart rate or status\n* Maternal or fetal indication for labor:\n\n  * Suspected Chorioamnionitis\n  * Suspected placental abruption\n  * Any maternal morbidity requiring labor\n* Cervical cerclage in place.\n* Major fetal malformation or known chromosomal abnormalities.\n* Stillbirth.\n* Sensitivity to Macrolides Antibiotics",
    "healthyVolunteers": false,
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": "50 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "A composite of neonatal adverse outcomes",
        "description": "A composite of neonatal adverse outcomes defined as the occurrence of one or more of the following events within 72 hours after birth:\n\nuse of continuous positive airway pressure (CPAP) or high-flow nasal cannula, supplemental oxygen with a fraction of inspired oxygen (FiO2) ≥0.30 for ≥4 continuous hours, extracorporeal membrane oxygenation (ECMO), mechanical ventilation, neonatal sepsis (defined as positive blood culture), hypoglycemia requiring treatment, hyperbilirubinemia requiring phototherapy, stillbirth, or neonatal death within 72 hours after delivery\n\nThe composite will be reported as the number of infants who experience at least one of the listed adverse outcomes.\n\nUnit of Measure: Number of infants with ≥1 adverse outcome",
        "timeFrame": "From the time of birth until 72 hours postpartum"
      }
    ],
    "secondary": [
      {
        "measure": "Number of Infants With Severe Respiratory Morbidity",
        "description": "Includes infants requiring CPAP or high-flow nasal cannula for ≥12 hours or mechanical ventilation, or neonatal death",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first."
      },
      {
        "measure": "Number of Infants Requiring Resuscitation at Birth",
        "description": "Any newborn requiring active resuscitation immediately after birth",
        "timeFrame": "At birth"
      },
      {
        "measure": "Number of Infants Diagnosed With Respiratory Distress Syndrome",
        "description": "Based on clinical signs, FiO₂ \\>0.21, and characteristic chest X-ray findings",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Infants Receiving Surfactant Therapy",
        "description": "Administration of surfactant during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first."
      },
      {
        "measure": "Number of Infants Diagnosed With Transient Tachypnea of the Newborn",
        "description": "Tachypnea resolving within 72 hours after birth",
        "timeFrame": "Within first 72 hours after birth"
      },
      {
        "measure": "Number of Infants Diagnosed With Necrotizing Enterocolitis",
        "description": "Clinical diagnosis of NEC during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first."
      },
      {
        "measure": "Number of Infants With Grade 3 or 4 Intraventricular Hemorrhage",
        "description": "Diagnosed by cranial ultrasound or imaging during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first."
      },
      {
        "measure": "Number of Infants With Feeding Intolerance",
        "description": "Clinical diagnosis of feeding intolerance during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first."
      },
      {
        "measure": "Number of Infants With NICU Stay Exceeding 3 Days",
        "description": "Length of NICU admission greater than three days",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Infants Diagnosed With Pneumothorax",
        "description": "Radiologically confirmed pneumothorax during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Infants Diagnosed With Meconium Aspiration Syndrome",
        "description": "Clinical diagnosis during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Infants Diagnosed With Birth Asphyxia",
        "description": "Clinical diagnosis of perinatal asphyxia during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Infants Diagnosed With Periventricular Leukomalacia",
        "description": "Diagnosed by imaging during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Infants With Neonatal Convulsions",
        "description": "Clinically diagnosed seizures during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Neonatal Deaths",
        "description": "Death of the newborn during hospitalization",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Distribution of Placental Histopathology Lesion Types",
        "description": "Classification of placental lesions according to standardized pathology criteria, including maternal vascular malperfusion lesions, fetal vascular malperfusion lesions, inflammatory lesions, and other abnormalities. Each placenta will be categorized based on pathology report",
        "timeFrame": "Within 6 weeks after delivery, upon receipt of pathology results"
      },
      {
        "measure": "Number of Infants With Positive Placental Cultures",
        "description": "Number of infants whose placental tissue culture was positive for bacterial growth",
        "timeFrame": "Within 6 weeks after delivery, upon receipt of culture results"
      },
      {
        "measure": "Distribution of Bacterial Species in Positive Placental Cultures",
        "description": "Identification and classification of bacterial species isolated from positive placental tissue cultures. Each positive culture will be categorized by bacterial genus and speciesWithin 4 weeks after delivery, upon receipt of culture results",
        "timeFrame": "Within 4 weeks after delivery, upon receipt of culture results"
      },
      {
        "measure": "Latency From Randomization to Delivery",
        "description": "Number of days from randomization until delivery",
        "timeFrame": "From randomization until delivery"
      },
      {
        "measure": "Number of Participants Completing Full Course of Antenatal Corticosteroids",
        "description": "Completion of full corticosteroid course for fetal lung maturity",
        "timeFrame": "From randomization until delivery"
      },
      {
        "measure": "Number of Participants With Placental Abruption",
        "description": "Clinically diagnosed placental abruption",
        "timeFrame": "From randomization until delivery"
      },
      {
        "measure": "Number of Participants With Intrapartum Fever (≥ 38°C)",
        "description": "Maternal fever occurring during labor",
        "timeFrame": "During labor"
      },
      {
        "measure": "Number of Participants Diagnosed With Clinical Chorioamnionitis",
        "description": "Diagnosis based on uterine tenderness and/or maternal fever related to suspected uterine infection",
        "timeFrame": "From randomization until delivery"
      },
      {
        "measure": "Number of Participants With Bacteremia (Positive Blood Culture)",
        "description": "Positive maternal blood cultures indicating bacteremia",
        "timeFrame": "From randomization until 72 hours postpartum"
      },
      {
        "measure": "Number of Participants Undergoing Unplanned Cesarean Delivery",
        "description": "Cesarean delivery not planned before labor onset",
        "timeFrame": "From randomization until delivery"
      },
      {
        "measure": "Number of Participants With Postpartum Endometritis",
        "description": "Clinical diagnosis of postpartum endometritis",
        "timeFrame": "From delivery until 6 weeks post partum"
      },
      {
        "measure": "Number of Participants With Postpartum Wound Infection or Dehiscence",
        "description": "Clinical diagnosis of wound infection or dehiscence after delivery",
        "timeFrame": "from birth and up to 6 weeks postpartum"
      },
      {
        "measure": "Number of Participants With Composite Adverse Maternal Outcome",
        "description": "A composite of maternal adverse outcomes defined as the occurrence of one or more of the following events within 6 weeks postpartum: bacteremia, ICU admission, hysterectomy, or need for drainage or relaparotomy",
        "timeFrame": "From randomization until 6 weeks postpartum"
      },
      {
        "measure": "Length of Postpartum Hospital Stay",
        "description": "Number of days hospitalized postpartum",
        "timeFrame": "From delivery through neonatal hospitalization or up to 28 days of life, whichever comes first"
      },
      {
        "measure": "Number of Participants Who Initiated Breastfeeding",
        "description": "Initiation of breastfeeding during hospital stay",
        "timeFrame": "From delivery through maternal hospital discharge or up to 28 days postpartum, whichever comes first"
      },
      {
        "measure": "Number of Participants Requiring Hospital Readmission",
        "description": "Any hospital readmission within 6 weeks postpartum",
        "timeFrame": "Up to 6 weeks postpartum"
      },
      {
        "measure": "Number of Participants With Antepartum Hemorrhage",
        "description": "Clinically diagnosed bleeding before delivery",
        "timeFrame": "From randomization until delivery"
      },
      {
        "measure": "Number of Participants With Uterine Rupture",
        "description": "Clinically diagnosed uterine rupture during labor or delivery",
        "timeFrame": "During labor or delivery"
      },
      {
        "measure": "Number of Participants With Umbilical Cord Prolapse",
        "description": "Clinically diagnosed cord prolapse",
        "timeFrame": "From randomization until delivery"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 34,
      "otherCount": 0,
      "totalCount": 35
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T05:06:11.774Z",
  "dataSource": "ClinicalTrials.gov API v2 - Ultimate Complete Collection"
}